Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology

John A. Thompson(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Bryan J. Schneider(University of Michigan), Julie R. Brahmer(Sidney Kimmel Comprehensive Cancer Center), Stephanie Andrews(Moffitt Cancer Center), Philippe Armand(Dana-Farber Brigham Cancer Center), Shailender Bhatia(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Lihua E. Budde(City Of Hope National Medical Center), Luciano J. Costa(University of Alabama at Birmingham), Marianne Davies(Smilow Cancer Hospital), David Dunnington(Roswell Park Comprehensive Cancer Center), Marc S. Ernstoff, Matthew J. Frigault(Massachusetts General Hospital), Brianna Hoffner(University of Colorado Cancer Center), Christopher Hoimes(Cleveland Clinic), Mario E. Lacouture(Memorial Sloan Kettering Cancer Center), Frederick L. Locke(Moffitt Cancer Center), Matthew A. Lunning(Susan Thompson Buffett Foundation), Nisha Mohindra(Fox Chase Cancer Center), Jarushka Naidoo(Sidney Kimmel Comprehensive Cancer Center), Anthony J. Olszanski(Fox Chase Cancer Center), Olalekan O. Oluwole(Breast Cancer Research Foundation), Sandip Pravin Patel(University of California San Diego), Sunil Reddy(Cancer Institute (WIA)), Mabel Ryder, Bianca Santomasso(Memorial Sloan Kettering Cancer Center), Scott Shofer(Cancer Institute (WIA)), Jeffrey A. Sosman(Fox Chase Cancer Center), Momen M. Wahidi(Cancer Institute (WIA)), Yinghong Wang(The University of Texas MD Anderson Cancer Center), Alyse Johnson-Chilla(National Comprehensive Cancer Network), Jillian L. Scavone(National Comprehensive Cancer Network)
Journal of the National Comprehensive Cancer Network
March 11, 2019
10.6004/jnccn.2019.0013
Cited by 560Open Access
Full Text

Abstract

The aim of the NCCN Guidelines for Management of Immunotherapy-Related Toxicities is to provide guidance on the management of immune-related adverse events resulting from cancer immunotherapy. The NCCN Management of Immunotherapy-Related Toxicities Panel is an interdisciplinary group of representatives from NCCN Member Institutions and ASCO, consisting of medical and hematologic oncologists with expertise in a wide array of disease sites, and experts from the fields of dermatology, gastroenterology, neuro-oncology, nephrology, emergency medicine, cardiology, oncology nursing, and patient advocacy. Several panel representatives are members of the Society for Immunotherapy of Cancer (SITC). The initial version of the NCCN Guidelines was designed in general alignment with recommendations published by ASCO and SITC. The content featured in this issue is an excerpt of the recommendations for managing toxicity related to immune checkpoint blockade and a review of existing evidence. For the full version of the NCCN Guidelines, including recommendations for managing toxicities related to chimeric antigen receptor T-cell therapy, visit NCCN.org.

Related Papers

No related papers found

Powered by citation graph analysis